BLRX vs. VRCA, TNYA, BLUE, RVPH, XLO, ATNM, SPRO, OSTX, IRD, and RNTX
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Verrica Pharmaceuticals (VRCA), Tenaya Therapeutics (TNYA), bluebird bio (BLUE), Reviva Pharmaceuticals (RVPH), Xilio Therapeutics (XLO), Actinium Pharmaceuticals (ATNM), Spero Therapeutics (SPRO), OS Therapies (OSTX), Opus Genetics (IRD), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.
BioLineRx vs.
Verrica Pharmaceuticals (NASDAQ:VRCA) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
BioLineRx received 340 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 71.61% of users gave BioLineRx an outperform vote while only 63.26% of users gave Verrica Pharmaceuticals an outperform vote.
Verrica Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.89 beat Verrica Pharmaceuticals' score of 0.93 indicating that BioLineRx is being referred to more favorably in the news media.
BioLineRx has higher revenue and earnings than Verrica Pharmaceuticals. BioLineRx is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals currently has a consensus target price of $9.50, suggesting a potential upside of 1,946.53%. BioLineRx has a consensus target price of $26.00, suggesting a potential upside of 649.28%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than BioLineRx.
BioLineRx has a net margin of -90.57% compared to Verrica Pharmaceuticals' net margin of -625.06%. BioLineRx's return on equity of -163.37% beat Verrica Pharmaceuticals' return on equity.
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
BioLineRx beats Verrica Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
This page (NASDAQ:BLRX) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy BLRX Stock Free BLRX Stock Alerts